title: A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.
abstract: OBJECTIVE
  This was a phase II study of perillyl alcohol in the treatment of advanced ovarian cancer. The primary endpoint was to evaluate the 6-month progression-free rate of perillyl alcohol as compared with historic controls. Secondary objectives were to evaluate the objective response rate, time to progression and survival, dropout rate, and number of cycles administered; define the qualitative nature of acute and chronic toxicities; and evaluate the effect of perillyl alcohol on triglycerides and total, HDL, and LDL cholesterol levels. Methods. Women who had received prior platinum-based therapy and had residual or recurrent disease were eligible. Perillyl alcohol was administered orally, four times daily, at a dose of 1200 mg/m(2). This was repeated until disease progression or unacceptable toxicity was experienced.
  
  
  RESULTS
  The 6-month progression-free rate was 17%. None of the patients achieved a complete or partial response. The median progression-free survival was 1.7 months. The median overall survival was 9.1 months. Compliance was greater than 90% but gastrointestinal toxicity (grade 1-2 nausea, satiety, eructation in 70%) and fatigue (grade 1-2 in 40%) were common and limited the ability to escalate the dose from 1200 to 1500 mg/m(2).
  
  
  CONCLUSIONS
  Perillyl alcohol administered at this dose and formulation did not exhibit signs of extending the time-to-progression in patients with advanced ovarian carcinoma.
authors.affiliation: University of Wisconsin-Madison, Madison, Wisconsin 53792, USA. hhbailey@facstaff.wisc.edu
authors.forename: Howard H
authors.initials: HH
authors.lastname: Bailey
authors.forename: Donna
authors.initials: D
authors.lastname: Levy
authors.forename: Linda S
authors.initials: LS
authors.lastname: Harris
authors.forename: Julian C
authors.initials: JC
authors.lastname: Schink
authors.forename: Francine
authors.initials: F
authors.lastname: Foss
authors.forename: Peter
authors.initials: P
authors.lastname: Beatty
authors.forename: Scott
authors.initials: S
authors.lastname: Wadler
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D039821:Monoterpenes; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D010349:Patient Compliance; D013729:Terpenes / Q000009:adverse effects / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D039821:Monoterpenes; D013729:Terpenes; D014280:Triglycerides; C032208:perillyl alcohol; D002784:Cholesterol